Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 78110-38-0] Aztreonam

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0129
Brand:	MCE
CAS:	78110-38-0

Overview

MDL	-
Molecular Weight	435.43
Molecular Formula	C13H17N5O8S2
SMILES	CC(C)(O/N=C(C1=CSC(N)=N1)\C(N[C@H]2[C@H](C)N(S(=O)(O)=O)C2=O)=O)C(O)=O

For research use only. We do not sell to patients.

5 Publications Citing Use of MCE

[1]Nat Commun. 2022 Mar 2;13(1):1116.
[2]Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18.
[3]Antibiotics (Basel). 2021, 10(11), 1341.
[4]Biomed Res Int. 2018 Jul 2;2018:3579832.
[5]Curr Microbiol. 2021 Dec 14;79(1):12.

Summary

Aztreonam (SQ-26,776) is a synthetic monocyclic beta-lactam antibiotic , which has a very high affinity for penicillin-binding protein 3 (PBP-3).

IC50 & Target

β-lactam

In Vitro

Aztreonam (SQ-26,776) is a synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum. It was approved by the U.S. Food and Drug Administration in 1986. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases. Aztreonam has no useful activity against gram-positive or anaerobic microorganisms ^[1] . Aztreonam (SQ-26) is similar in action to penicillin. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidogly can crosslinking. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam (SQ-26) binds the penicillin-binding proteins of gram-positive and anaerobic bacteria very poorly and is largely ineffective against them. Aztreonam (SQ-26) is bactericidal but less so than some of the cephalosporins ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03376529	Spero Therapeutics\|Simbec Research\|QPS	Healthy Volunteers	November 10, 2017	Phase 1
NCT03158116	UCSF Benioff Children´s Hospital Oakland\|Gilead Sciences	Tracheostomy Infection	July 1, 2017	Phase 4
NCT03696290	University of Dundee\|Gilead Sciences	Bronchiectasis Adult	October 19, 2019	Phase 2
NCT01375049	Gilead Sciences	Cystic Fibrosis	August 2011	Phase 2
NCT01460836	Novartis Pharmaceuticals\|Novartis	Cystic Fibrosis	April 2010
NCT00424190	Forest Laboratories	Bacterial Infections	February 2007	Phase 3
NCT01689207	Pfizer	Complicated Infection\|Bacterial Infections	September 2012	Phase 1
NCT01499277	Pfizer\|Forest Laboratories	Complicated Skin and Soft Tissue Infection	May 2012	Phase 3
NCT00423657	Forest Laboratories	Bacterial Infections	March 2007	Phase 3
NCT02276482	Cubist Pharmaceuticals LLC	Skin Diseases, Infectious\|Skin Diseases, Bacterial	March 25, 2015	Phase 3
NCT00989807	Gilead Sciences	Cystic Fibrosis\|Pseudomonas Aeruginosa
NCT00757237	Gilead Sciences\|Chiltern International Inc.\|ClinPhone, Inc.\|Covance	Cystic Fibrosis	August 2008	Phase 3
NCT03749226	Hospital Universitari Joan XXIII de Tarragona.	Ventilator Associated Pneumonia\|Prevention\|Respiratory Infection Other	March 19, 2019	Phase 2\|Phase 3
NCT01400867	Forest Laboratories\|AstraZeneca	Infections, Pediatrics	December 2011	Phase 2\|Phase 3
NCT01055847	Gilead Sciences\|Salus Pharma, Inc.	Cystic Fibrosis\|CF\|Lung Infection\|Pseudomonas Aeruginosa	June 2003	Phase 2
NCT00633152	Forest Laboratories	Bacterial Infection	February 2008	Phase 2
NCT01984684	Melinta Therapeutics, Inc.	Skin and Subcutaneous Tissue Bacterial Infections\|Skin Structures and Soft Tissue Infections	May 2014	Phase 3
NCT03867734	University of Washington	Gonorrhea of Pharynx\|Gonorrhea	April 5, 2019	Phase 2\|Phase 3
NCT02894684	Liverpool Heart and Chest Hospital NHS Foundation Trust\|University of Liverpool	Cystic Fibrosis\|Infection\|Pseudomonas	January 2017	Phase 4
NCT01469364	Duke University\|Gilead Sciences	Complication of Transplanted Lung	March 2013	Phase 4
NCT00499720	Gilead Sciences	Cystic Fibrosis\|Pseudomonas Aeruginosa Airway Infection
NCT01659866	Northwestern University	Infection	August 2012	Phase 4
NCT01811732	Melinta Therapeutics, Inc.	Skin and Subcutaneous Tissue Bacterial Infections	April 2013	Phase 3
NCT00228410	Wyeth is now a wholly owned subsidiary of Pfizer	Skin Diseases, Infectious	November 2002	Phase 3
NCT02202135	Pfizer\|Forest Laboratories	Complicated Skin and Soft Tissue Infection	June 2014	Phase 3
NCT02730793	Virginia Commonwealth University\|Eastern Virginia Medical School	Cystic Fibrosis	January 2017	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 114.83 mM ; Need ultrasonic)

H ₂ O : 10 mg/mL ( 22.97 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2966 mL	11.4829 mL	22.9658 mL
5 mM	0.4593 mL	2.2966 mL	4.5932 mL
10 mM	0.2297 mL	1.1483 mL	2.2966 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 10 mg/mL (22.97 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Kobayashi Y, et al. Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood. J Antimicrob Chemother. 1992 Dec;30(6):871-2.
[2] Guay DR, et al. Aztreonam, a new monobactam antimicrobial. Clin Pharm. 1985 Sep-Oct;4(5):516-26.

Synonyms

Propanoic acid, 2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl-

Propanoic acid, 2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methyl-, [2S-[2α,3β(Z)]]-

2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid

SQ 26776

Azthreonam

Antibiotic Squibb 26,776

Squibb 26776

Aztreonam

Nebactam

Aztreon

Primbactam

Azonam

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart